Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

nformation identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.Selected Financial DataConsolidated Statements of Operations DataThree Months EndedSeptember 30,Nine Months Ended September 30,(In thousands, except per share data)2010200920102009(unaudited)(unaudited)Revenues:Collaborative research$  632$  1,650$  3,437$  8,042Subscription and license fees1494812181,246Total revenues7812,1313,6559,288Operating expenses:Research and development, including stock-based compensation

of $751, $733, $2,366 and $2,328, respectively20,08619,32061,41362,404General and administrative, including stock-based compensation

of $582, $547, $1,592 and $1,750, respectively4,9484,56815,53514,993Total operating expenses25,03423,88876,94877,397Loss from operations(24,253)(21,757)(73,293)(68,109)Gain on investments, net-1851411,008Interest income51103468669Interest expense(637)(785)(2,093)(2,180)Other expense, net(2,700)(516)(4,025)(2,037)Consolidated loss before taxes(27,539)(22,770)(78,802)(70,649)Income tax benefit2610226102Consolidated net loss(27,513)(22,668)(78,776)(70,547)Less: Net loss attributable to noncontrolling interest in Symphony Icon, Inc.-3,526-9,772Net loss attributable to Lexicon Pharmaceuticals, Inc.$  (27,513)$  (19,142)$  (78,776)$  (60,775)Net loss  attributable to Lexicon Pharmaceuticals, Inc. per common share, basic and diluted$   (0.08)$  (0.14)$  (0.27)$  (0.44)Shares used in computing net loss attributable to Lexicon Pharmaceuticals, Inc.  per common share, basic and diluted337,404137,
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon to Present at Two Major Healthcare Investor Conferences
4. Lexicon Announces Pricing of Common Stock in Public Offering
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... , July 10, 2014  Franciscan ... use of capnography for respiratory monitoring outside ... of healthcare leaders in embracing state-of-the-art patient ... effectively patients are breathing and can alert ... By measuring the amount of carbon dioxide ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... 5 DURECT Corporation,(Nasdaq: DRRX ) announced today ... 31, 2007. Total revenues were $6.6 million for the,three ... for the same,period in 2006. Net loss for the ... to a net loss of $9.8 million for the ...
... ST. LOUIS, Feb. 5 Monsanto Company,s ... global commercial,business, and Carl Casale, executive vice ... in separate presentations at two,conferences later this ... an update on the company,s,business performance and ...
... BEIJING and CLAREMONT, Calif., Feb. 5 /Xinhua-PRNewswire-FirstCall/ ... Board: KWBT) reports,on a meeting between Kiwa ... and Dr.,Xiao-Dong Huang from the Department of ... the possibility of collaboration in research and,development ...
Cached Biology Technology:DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 2DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 4DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 5DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 6DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 7DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 8DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 9Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 2Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 3
(Date:7/11/2014)... Institute of Standards and Technology (NIST) need a ... they often prove that necessity is truly the ... for M. Lorna De Leoz and Stephen Stein, ... glycomics. Glycomics is the study of the abundant, ... to proteins and lipids and influence cellular processes, ...
(Date:7/11/2014)... July 3, 2014, Shenzhen, China Researchers from Salk ... for the first time evaluated the safety and ... and successfully developed a new method, TALEN-HDAdV, which ... pluripotent stem cell (hiPSC). This study published online ... important theoretical foundation for stem cell-based gene therapy. ...
(Date:7/11/2014)... researchers, including scientists from the Max Planck Institute for ... major step in understanding photosynthesis, the process by which ... in its atmosphere and which is therefore crucial for ... The researchers report the first direct visualization of a ... in which a specific protein complex, photosystem II, splits ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2A first direct glimpse of photosynthesis in action 2
... LA JOLLA, CA---- Researchers at the Salk Institute for Biological ... skin cells and turned them into induced pluripotent stem cells ... form any other cell or tissue in the body. ... Shinya Yamanaka at Kyoto University in Japan, and human iPSCs ...
... Calif.) It happens in military units, street gangs ... cultures, the rituals mark the transition from adolescence to ... given. With a long history of seemingly universal ... puzzle. Why have so many cultures incorporated it into ...
... market to treat leukemia reversed symptoms of colitis in lab ... the University of Alberta. Faculty of Medicine & Dentistry ... journal, PLOS ONE . His team ... role in the development of colitis. When this gene quits ...
Cached Biology News:Induced pluripotent stem cells reveal differences between humans and great apes 2Induced pluripotent stem cells reveal differences between humans and great apes 3UCSB anthropologist examines the motivating factors behind hazing 2UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3